AMI, or rule-out AMI, and meeting electrocardiographic, laboratory, and clinical criteria suggestive of AMI were reviewed to determine the proportion of eligible patients who received thrombolytic, \g=b\-blocker,aspirin, and lidocaine hydrochloride therapy. The effects of patient age, gender, and hospital teaching status on the use of these treatments were estimated using logistic regression models.
Background: Evidence-based guidelines for the treatment of patients with acute myocardial infarction (AMI) have been published and disseminated by the American College of Cardiology and the American Heart Association. Few studies have examined the rates of adherence to these guidelines in eligible populations and the influence of age and gender on highly effective AMI treatments in community hospital settings.
Methods: Medical records of 2409 individuals admitted to 37 Minnesota hospitals between October 1992 and July 1993 for AMI, suspected AMI, or rule-out AMI, and meeting electrocardiographic, laboratory, and clinical criteria suggestive of AMI were reviewed to determine the proportion of eligible patients who received thrombolytic, \g=b\-blocker,aspirin, and lidocaine hydrochloride therapy. The effects of patient age, gender, and hospital teaching status on the use of these treatments were estimated using logistic regression models.
Results: Eligibility for treatment ranged from 68% (n=1627) for aspirin therapy, 38% (n=906) for lidocaine therapy, and 30% (n=734) for thrombolytic therapy to 19% (n=447) for \g=b\-blockertherapy. Seventy-two per-cent of patients eligible to receive a thrombolytic agent received this therapy; 53% received \g=b\-blockers;81% received aspirin; and 88% received lidocaine. Among patients ineligible for lidocaine therapy (n=1503), 20% received this agent. Use of study drugs was lower among eligible elderly patients, especially those older than 74 years (thrombolytic agent: odds ratio, 0.2; 95% confidence interval, 0.1 to 0.4; aspirin: odds ratio, 0.4, 95% confidence interval, 0.3 to 0.6;\g=b\-blocker:odds ratio, 0.4; 95% confidence interval, 0.2 to 0.8). Female gender was associated with lower levels of aspirin use among eligible patients (odds ratio, 0.7; 95% confidence interval, 0.6 to 0.9); and there was a trend toward lower levels of \g=b\-blocker and thrombolytic use among eligible women.
Conclusions: Use of lifesaving therapies for eligible patients with AMI is higher than previously reported, particularly for aspirin and thrombolytic use in nonelderly patients. Lidocaine is still used inappropriately in a substantial proportion of patients with AMI. Increased adherence to AMI treatment guidelines is required for elderly patients and women.
(Arch Intern Med. 1996;156:799-805)
DESPI TE
A recent decline in the rate of cardiovascu¬ lar mortality, acute myocardial infarction (AMI) remains the leading cause of death in the United States.1 Random¬ ized controlled trials2"7 of patients with AMi provide strong and consistent evidence that early administration of several drug thera¬ pies, including thrombolytic agents, aspi¬ rin, and ß-blockers, substantially reduce mortality and other adverse events. Re¬ cent data8 also indicate that other com¬ mon AMI treatments, such as prophylac¬ tic use of lidocaine hydrochloride, which reduces the likelihood of primary ven¬ tricular fibrillation, may lead to in¬ creased mortality, especially in uncompli¬ cated AMI. Nevertheless, lidocaine continues to be used in patients for whom there is no evidence of proven benefit. Na¬ tional evidence-based guidelines for the early management of patients with AMI have been published and disseminated.9
However, a critical review10 of welldesigned studies, which examined the ef¬ fectiveness of interventions aimed at im¬ proving drug-prescribing behaviors, has shown that the dissemination of printed materials alone appears ineffective in changing physicians' clinical practice, sug-. gesting that adoption of practice recom¬ mendations may be suboptimal.
Earlier This investigation measured consistency of physician pre¬ scribing with guideline recommendations during the acute phase of illness. Patients were identified through medical chart review of diagnoses and clinical and laboratory find¬ ings at admission rather than at discharge. This avoided the problem of evaluating care for patients presenting atypically and often not diagnosed with AMI until later in the hospital stay.
The pool available for screening included 4968 pa¬ tients with a diagnosis of AMI, suspected AMI, or rule-out AMI admitted to the 37 study hospitals during the study period. Patients were included in the study if they met at ¡east two of the following criteria for AMI: (1) an electro¬ cardiogram (ECG) with positive findings (defined as phy¬ sician documentation that ECG was consistent with AMI (ie, Q-wave or T-wave inversion, or ST-segment depres¬ sion or elevation al mm); (2) positive enzyme evidence (elevation of the isoenzyme muscle-brain [MB] subfrac¬ tion of creatine kinase); or (3) clinical symptoms (arm or shoulder pain, chest pain, diaphoresis, dyspnea, nausea or vomiting, or neck/jaw pain consistent with cardiac ische¬ mia). Patients were excluded from the study if they were dead on arrival, were transferred from a nonstudy hospi¬ tal, or had suffered an AMI 2 weeks before the index ad¬ mission.
INDICATIONS AND CONTRAINDICATIONS FOR STUDY DRUGS
All absolute and relative contraindications as well as indications for use of thrombolytic agents, aspirin, ß-blockers, and lidocaine were summarized by a panel of cardiologists and internists on the research team ( Figure premature ventricular contractions) were present for more than 98% of all patients. Because the treatment recommendation for lidocaine is controversial, we used a liberal definition of eligibility in accord with guidelines by the American College of Cardiology and the Ameri¬ can Heart Association (Figure 1 ). of AMI based on administrative claims or registry data examined gross use of effective AMI therapies. In these studies, however, information on indications or con¬ traindications to therapy was limited; therefore, patient eligibility for specific AMI therapies could not be established. Two recent reports,1316 however, did establish eligibility but only for the elderly, who make up only about half of all patients with AMI. Because of these limitations, levels of appropriate use of thrombolytic agents, aspirin, ß-blockers, and other lifesaving therapies may have been underestimated, and the quality of AMI pharmacotherapy in large samples of patients of all ages in community hospitals remains unknown.
This study reports rates of adherence to consensus guideline recommendations for aspirin, ß-blocking agents, lidocaine, and thrombolytic agents among 2409 pa¬ tients with AMI treated at 37 Minnesota hospitals from October 1992 to July 1993. We focused on physician de-cisión making in the context of suspected or confirmed AMf immediately after presentation (intention to treat).
In addition, we determined whether patient age, gen¬ der, hospital location (urban vs nonurban), or hospital teaching status was related to rates of adherence to the published practice guidelines.
RESULTS

PATIENT SAMPLE
Among 4968 patients admitted for suspected AMf, 48% (n=2409) met criteria for study inclusion. The median and mean numbers of study patients per hospital were 42 and 65, respectively. The baseline characteristics of study patients are presented in Table 1 .
Ninety-two percent of study patients had a dis¬ charge diagnosis of AMI, indicating a high predictive value of the algorithm in identifying patients at admis-
DEVELOPMENT OF ABSTRACTING INSTRUMENT
The medical record abstraction instrument was designed to retrieve data on demographics; admission and discharge dates; insurance status; inclusion and exclusion criteria; admis¬ sion data, including initial medical contact, time from first symptoms to hospital presentation; diagnostic impressions; identities of all medications taken before admission; inpatient procedures; ECG evidence of AMI; laboratory evi¬ dence of AMI; medical history at admission; clinical find¬ ings (symptoms and physical findings) on presentation and during the first 24 hours of hospitalization; and identity and time of administration of all drugs in the first 48 hours of ad¬ mission, including during emergency transport and in the emergency department. Indications and contraindications for all study drugs were able to be developed from the informa¬ tion in the above categories. To increase sensitivity for sev¬ eral important contraindications (congestive heart failure, un¬ controlled hypertension, etc), we abstracted data from both physicians' and nurses' notes.
DATA COLLECTION AND INTEGRITY
Nurses experienced in the care of patients with AMI per¬ formed all data collection for this study. Successful abstrac¬ tors were required to complete 2 days of training and data collection exercises, and demonstrate initial and ongoing in¬ terrater agreement with a criterion review of 95% or higher. Retrospective audits of a random sample of 10% of each ab¬ stractor's completed cases were conducted to ensure that each abstractor met and maintained the data quality standard of 95% all-item agreement with the MCCAP auditor. Abstrac¬ tors falling below this standard after additional training were released, and their charts were reabstracted.
We tested the validity of chart-based ECG informa¬ tion indicating thrombolytic treatment (ST segment, el¬ evation Si mm in two or more contiguous leads, exclud¬ ing changes consistent with early repolarization or pericarditis; or new or presumably new left bundlebranch block) by collecting the first two ECG tracings for a 25% random sample of study patients (n=534). Two in¬ dependent cardiologists blind to the original ECG read-ings reviewed and interpreted ECG tracings of the 25% ran¬ dom sample. We then calculated the congruence between indication of ST-segment elevations of 1 mm or more in the medical chart (yes or no) with the cardiologists' reviews of the tracings (yes or no).
DESCRIPTION OF ANALYTICAL MODELS
For analysis, we defined eligibility as the absence of abso¬ lute or relative contraindications to aspirin, ß-blockers, li¬ docaine, and thrombolytic agents as well as the presence of the appropriate indication (Figure 1 ). For example, af¬ ter we excluded patients with medical contraindications, eligibility for use of thrombolytic agents was further re¬ stricted to patients presenting within 12 hours of onset of symptoms and with an ST-segment elevation of 1 mm or more. Adherence to guidelines (yes or no) for use of throm¬ bolytic agents, ß-blockers, and aspirin was defined as re¬ ceipt of drug by an eligible patient within 24 hours of first contact with the hospital. We calculated observed adher¬ ence rates for each medication as the proportion of eli¬ gible patients receiving thrombolytic agents, ß-blockers, or aspirin. For the purposes of this study, we defined nonadherence to lidocaine treatment guidelines as use among pa¬ tients without the previously described indications.
To examine the association of patient and hospital characteristics with guideline adherence rates, we ana¬ lyzed patient and hospital-level data for each study drug. A logistic regression model was used that controlled for correlation of binary observations (adherence to guide¬ lines, yes or no) within hospitals.18 Regression models included terms for patient gender; patient age interval (<65, 65 to 74, >74 years); teaching status of hospital; and urban vs nonurban location of the hospital. Odds ratios (OR) and confidence intervals (CI) were calcu¬ lated directly from the estimated regression coefficients and their SEs. Adjusted proportions for receipt of the study drugs among eligible patients (or ineligible patients in the case of lidocaine) were estimated using the coefficients of the logistic regression analysis and represent estimated proportions controlling for the pres¬ ence of all patient and hospital study variables. sion with suspected AMI. To further validate the abstracted ECG information used for identifying ST elevation (indication for thrombolytic therapy), we compared the medical record interpretation of ECG tracings with those performed by research team cardi¬ ologists. Among 250 patients with medical record documentation of ST-segment elevation, both cardi¬ ologist reviewers agreed with this interpretation in 86% of cases, a high level of concordance considering that cardiologists had access to only the first two ECG tracings in the medical chart.
OVERALL RATES OF ADHERENCE TO AMI TREATMENT GUIDELINES
After controlling for all other characteristics in the regression models, the largest gaps in adherence to treatment guidelines among eligible patients were observed for thrombolytic agents and ß-blockers. Seven hundred thirty-four of the 2409 patients were eligible for thrombolytic therapy, but only 72% of patients eligible to receive thrombolytic therapy actu¬ ally received this therapy. Of 447 (19%) of the 2409 study patients eligible to receive ß-blockers, 237 (53%) received therapy in the first 24 hours. However, the main reasons for ineligibility for these drugs were often transitory conditions such as bradyarrhythmias and hypotension.
Thirty-eight percent of study patients (n=906) had a medical record documentation of a 30-second run of sustained ventricular tachycardia of more than 100 bpm, ventricular fibrillation, nonsustained ven¬ tricular tachycardia, or frequent premature ventricular contractions; 88% of these individuals received lido¬ caine. However, among those with no indication (n=1503), 300 (20%) received this potentially harmful drug. Aspirin was administered to 1318 (81%) eligible patients.
ORAL ASPIRIN
Indication: All patients with AMI and without any contraindications.
Absolute Contraindications: History of allergy to aspirin; serious gastrointestinal bleeding-hematemesis; blood in nasogastric aspirate.
Relative Contraindications: Asthma (with nasal polyps); history of bleeding/significant risk of bleeding; history of peptic ulcer disease.
ß-BLOCKERS
Absolute Contraindications: Bradycardia (<60 beats per minute); low systolic blood pressure (<100 mm Hg); severe left ventricular failure (rales greater than 10 cm from base of lungs [10 cm=1/3 from base]); severe bronchospastic lung disease; signs of peripheral hypoperfusion; atrioventricular condition abnormalities; history of adverse reaction to ß-blockers.
Relative Contraindications: Systolic blood pressure <110 mm Hg; history of asthma; current use of verapamil or diltiazem; severe peripheral vascular disease; difficult-to-control, severe, insulin-dependent diabetes.
THROMBOLYTIC AGENTS
Indications: All patients with AMI or suspected AMI presenting within 12 hours of onset of symptoms; ST-segment elevation > 1 mm; no medical contraindications.
Absolute Contraindications: Active internal bleeding; suspected aortic dissection; prolonged or traumatic cardiopulmonary resuscitation; ¡ntracranial neoplasm; hemorrhagic ophthalmic conditions; pregnancy; previous allergic reaction to the thrombolytic agent; sustained systolic blood pressure >180mm Hg; or diastolic blood pressure >110 mm Hg; any recorded blood pressure >200/120 mm Hg on admission; trauma or surgery in past 2 weeks; AMI onset >24 hours.
Relative Contraindications: Major bleeding; recent trauma or surgery >2 weeks; history of chronic severe hypertension with or without drug therapy; history of cerebrovascular accident; current use of warfarin anticoagulants; prior use of streptokinase or APSAC; significant liver dysfunction; active peptic ulcer; AMI onset >12 hours.
LIDOCAINE HYDROCHLORIDE
Indications: Patients with AMI (ACC/AHA class I) or suspected AMI (ACC/AHA class lia) with frequent (>6) ventricular premature beats; nonsustained or sustained (>30 seconds) ventricular tachycardia at a rate >100 bpm; ventricular fibrillation.
Absolute Contraindications: Allergy to lidocaine. *AMI indicates acute myocardial infarction; ECG, electrocardiogram; and HMO, health maintenance organization.
EFFECT OF PATIENT AGE ON RATES
OF ADHERENCE TO GUIDELINES Figure 2 illustrates unadjusted guideline adherence rates for the study drugs by age interval among patients eli¬ gible to receive aspirin, ß-blockers, and thrombolytic agents. In general, we observed a trend toward reduced use of study drugs with increasing age. Table 2 presents adjusted proportions and ORs for receipt of the study drugs by patient age category and other study characteristics, controlling for all other patient and hospital characteristics. For all four drugs, patients aged 75 years or older were significantly less likely to be treated than those aged 64 years or younger, regardless of whether the agent was likely to be beneficial (aspirin, ß-block¬ ers, thrombolytic agents) or ineffective (lidocaine). This level of undertreatment of those aged 75 years or older was most pronounced for thrombolytic agents (OR, 0.2; 95% CI, 0.1 to 0.4) although significantly lower levels of ß-blockers (OR, 0.4; 95% CI, 0.2 to 0.9) and aspirin (OR, 0.4; 95% CI, 0.3 to 0.6) were also observed. In¬ appropriate lidocaine administration was also lower among those aged 75 years or older compared with those younger than 65 years (OR, 0.6; 95% CI, 0.6 to 0.8).
We also observed a nonsignificant trend toward lower use of ß-blockers and thrombolytic agents among the "young-old" (aged 65 to 74 years) in comparison with nonelderly patients (estimated proportions of 80% vs 76% for thrombolytic agents, P=.08; 60% vs 51% for ß-blockers, P=.33; Table 2 ). Aspirin use was signifi¬ cantly lower among those aged 65 to 74 years com¬ pared with those younger than 65 years (OR, 0.7; 95% CI, 0.5 to 0.9).
EFFECT OF PATIENT GENDER ON RATES OF ADHERENCE TO GUIDELINES
Among patients eligible for treatment, use of all study drugs was consistently lower for women than for men (Figure 3 ). After adjusting for age and hospital type, women were less likely to be treated with aspirin (OR, 0.7; 95% CI, 0.6 to 0.9) and thrombolytic agents (OR, 0.7; 95% CI, 0.6 to 1.0) than men ( Table 2 ). A similar trend was observed for those treated with ß-blockers and lidocaine ( Table 2 ).
EFFECT OF HOSPITAL TYPE ON RATES OF ADHERENCE TO GUIDELINES
In general, we did not observe consistent differences in adherence to treatment guidelines for aspirin, ß-block¬ ers, thrombolytic agents, or lidocaine among urban, teach¬ ing hospitals, urban, nonteaching hospitals, and nonurban, nonteaching hospitals (Figure 4 ). After controlling for patient characteristics, the largest effect of hospital type on guideline adherence patterns was for use of li¬ docaine among patients without indication for this therapy (Table 2 ). Urban, teaching hospitals were approxi¬ mately four times less likely than urban, nonteaching to use lidocaine inappropriately (OR, 0.2; 95% CI, 0.1 to 0.6).
COMMENT
The present study represents the largest investigation to date of rates of adherence to national AMI drug treat- Figure 2 . Guideline adherence among eligible patients by age category. nearly 2500 medical records of patients presenting with suspected AMI and with clinical and ECG evidence of AMI, we were able to overcome the limitations of prior reports based solely on information recorded in claims or myocardial infarction registry data. Two recent stud¬ ies1316 of AMI treatment patterns among the elderly re¬ ported use of thrombolytic agents and other AMI drug treatments; one of these reports related drug use to shortterm mortality although sample sizes were very small and patients were clustered within six hospitals. Because nonelderly patients with AMI represent approximately one half of all heart attack victims,19 we included this impor¬ tant patient population in this study. We found that among all patients with AMI, eligibil¬ ity for treatment ranged from 68% for aspirin use, 38% for lidocaine use, and 30% for thrombolytic use to 19% for ß-blocker use. When relative medical contraindications were dropped as reasons for ineligibility, 96% of all patients with AMI were eligible to receive aspirin; 33% were eligible to receive thrombolytic agents; and 24% were eligible to re¬ ceive ß-blockers. Among 2409 patients, only 398 had a pre¬ existing disease or history contraindicating use of throm¬ bolytic agents; of those without such contraindications, 620 presented beyond 12 hours after onset of symptoms. An¬ other 598 presented within 12 hours of onset of symp¬ toms but did not have ST-segment elevations on ECG.
The observation that only 447 (19%) patients were eligible to receive ß-blockers is conservative. Since the main reasons for exclusion from ß-blocker eligibility were sustained bradyarrhythmia and hypotension at hospital presentation, it is likely that a number of patients expe¬ rienced these conditions for only a limited period, thus becoming eligible to receive ß-blockers subsequently.
Among populations eligible for effective, lifesaving drugs, we observed moderately high rates of use of aspirin (81%), moderate use of thrombolytic agents (72%), and low use of ß-blockers (53%). Twenty per¬ cent of patients without indication for lidocaine received this potentially harmful agent. Although previ¬ ous studies11"13 have examined utilization rates of aspi- tin, ß-blockers, lidocaine, and thrombolytic agents among total populations of patients with AMI, data limitations in those investigations precluded investigators from de¬ fining absolute or relative contraindications and so es¬ tablish appropriateness of therapy. Failure to define drugspecific eligible populations may lead to biased conclusions (eg, that treatments like thrombolytic agents are used in only a "minority of AMf patients,"20 or among very small fractions of the elderly).
After controlling for the presence of all indications and contraindications, we found that, on average, ad¬ herence to guidelines by the American College of Car¬ diology and the American Heart Assocation during the study period was higher (63%) than reported in previ¬ ous studies even for thrombolytic agents in those older than 65 years. A recent study of more than 65 000 el¬ derly patients with first heart attacks between 1988 and 1992 found that thrombolytic use increased from 11% to 18% from 1988 to 1990, and plateaued at this level through 1992; the gross utilization rate among elderly patients in this previous study was approximately 20% for those aged 65 to 69 years and approximately 15% for those aged 70 to 74 years. In our study, similar propor¬ tions of total (eligible plus ineligible) elderly patients with AMI received thrombolytic agents (28%), but 63% of eli¬ gible elderly patients were treated with these agents. These discrepancies underline the need to define treatment eli¬ gibility to measure meaningful utilization rates. Results that we report for thrombolytic use among eligible elderly patients were not significantly influenced by the use of emergency revascularization procedures. When angioplasty and coronary artery bypass surgery oc¬ curring within 24 hours of admission were included in the analysis, only a small change in overall adherence rates (<3%) was observed. Do-not-resuscitate orders did not significantly affect treatment adherence rates for use of thrombolytic agents (or other drugs). For example, of 332 patients with do-not-resuscitate orders, only three were eligible to receive thrombolytic agents, and one was eli¬ gible to receive ß-blocker therapy.
We observed consistent relationships between pa¬ tient characteristics, especially age and gender, and guide¬ line adherence. Prior research has demonstrated that an- giography, coronary artery bypass graft surgery, and percutaneous transluminal coronary angioplasty de¬ cline with increasing age; these cardiac procedures were also less common among women than among men. 13 The present report indicates that reduced levels of use of ef¬ fective therapies persisted in elderly patients even when treatment eligibility, gender, and hospital characteris¬ tics were controlled for in the analysis. Among eligible patients, those aged 75 years or older were only 60% as likely as younger patients to receive thrombolytic treatment despite the reports from randomized controlled tri¬ als that these agents are associated with an additional 10 lives saved per 1000 treated for those aged 65 to 74 years. 21 Similarly, the OR of administration of aspirin and ß-blocker therapy among those aged 65 to 74 years vs younger patients was 0.67 and 0.70, respectively, and this pattern of underuse of effective AMf treatments among eligible patients was even more pronounced in the 75 and older age category. Female patients were also at in¬ creased risk of undertreatment, corroborating results ob¬ served in Medicare populations.1113 These patterns of un¬ deruse among the elderly and women are particularly intriguing since these populations have been typically underrepresented in randomized controlled trials. 3, 22 In general, neither a hospital's teaching status nor its location (urban vs nonurban) influenced utilization rates of the study drugs. However, clinicians in urban teaching hospitals were less likely to prescribe lidocaine inappropriately than in urban nonteaching hospitals, and aspirin use was lower in nonurban areas.
Although use of lifesaving therapies for eligible pa¬ tients with AMI is higher than previously reported, fur¬ ther improvements in guideline adherence rates, espe¬ cially among elderly people and women, could lead to even further improvement in survival and morbidity for this major disease. Innovative clinician education and sys¬ tems improvements, aimed at increasing use of effective agents, need to be developed and tested in combination with public education aimed at early recognition of AMI. Government and private health care programs could then be encouraged to adopt the most cost-effective initia¬ tives that can reduce mortality and morbidity resulting from this major disease.
